Sorlí, LuisaLuque Pardos, SòniaLi, JianBenítez-Cano, AdelaFernández, XeniaPrim, NúriaVega, VictoriaGómez Junyent, JoanLópez Montesinos, InmaculadaGómez-Zorrilla, SilviaMontero, Maria MilagroGrau Cerrato, SantiagoHorcajada Gallego, Juan Pablo2024-10-292024-10-292023Sorlí L, Luque S, Li J, Benítez-Cano A, Fernández X, Prim N, et al. Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa. Microbiol Spectr. 2023 Dec 12;11(6):e0296723. DOI: 10.1128/spectrum.02967-232165-0497http://hdl.handle.net/10230/68379In some cases, colistin is the only treatment option for infections caused by the very drug-resistant Pseudomonas aeruginosa. However, in the past decade, there have been questions concerning its pharmacokinetics and concentration at the site of infection. In this scenario, its use in a difficult-to-treat infection like pneumonia is currently debatable. This is a clinical pharmacokinetic study of colistin in patients with multidrug-resistant P. aeruginosa pneumonia. Our findings demonstrate that colistin exposure is associated with worse clinical outcomes rather than better clinical outcomes, implying that other therapeutic options should be explored in this clinical setting.application/pdfeng© 2023 Sorlí et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.1128/spectrum.02967-23Pseudomonas aeruginosaColistinPharmacokineticsPneumoniainfo:eu-repo/semantics/openAccess